Citicoline and Vitamin B12 Eye Drops in Type 1 Diabetes: Results of a 36-Month Pilot Study Evaluating Macular Electrophysiological Changes.

What Was Tested

This randomized controlled trial looks at Cyanocobalamin (Vitamin B12).

Who Took Part

The abstract describes 10 patients taking part.

How the Study Was Run

The researchers set it up as a randomized, placebo-controlled and pilot study.

The patients were allocated by chance, so the Cyanocobalamin (Vitamin B12) group and the comparison group should start out alike.

Some patients received a placebo instead of Cyanocobalamin (Vitamin B12), giving a reference point.

It is described as a pilot, a small early test of whether a larger Cyanocobalamin (Vitamin B12) study would be practical.

A prospective, randomized, interventional, monocentric, double-masked study was conducted.

A total of 18 eyes (10 from the DP and 8 from the DC group, respectively) completed the study.

In mfERG analysis, the N1-P1 response amplitude density (RAD) evaluated in the 0-2.5° (ring 1), in the 2.5-5° (ring 2), in the 5-10° (ring 3), and in the 0-10° (ring 1 + ring 2 + ring 3) were considered.

What Was Measured

The subject headings attached to it are Cytidine Diphosphate Choline, Diabetes Mellitus, Type 1, Diabetic Retinopathy, Italy, Ophthalmic Solutions, Pilot Projects and Retina.

The authors tagged it with the keywords Citicoline, Multifocal electroretinogram, Ophthalmology and Vitamin B12.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and pilot study of Cyanocobalamin (Vitamin B12) in 10 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (Advances in therapy), a journal based in United States.

More context: the Cyanocobalamin (Vitamin B12) compound page, all human trials.